FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:580-591 February 7, 2008 Number 6 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set CME Exam Supplementary Material Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Intensified multifactorial intervention — with tight glucose regulation and the use of renin–angiotensin system blockers, aspirin, and lipid-lowering agents — has been shown to reduce the risk of nonfatal cardiovascular disease among patients with type 2 diabetes mellitus and microalbuminuria. We evaluated whether this approach would have an effect on the rates of death from any cause and from cardiovascular causes.

Methods In the Steno-2 Study, we randomly assigned 160 patients with type 2 diabetes and persistent microalbuminuria to receive either intensive therapy or conventional therapy; the mean treatment period was 7.8 years. Patients were subsequently followed observationally for a mean of 5.5 years, until December 31, 2006. The primary end point at 13.3 years of follow-up was the time to death from any cause.

Results Twenty-four patients in the intensive-therapy group died, as compared with 40 in the conventional-therapy group (hazard ratio, 0.54; 95% confidence interval [CI], 0.32 to 0.89; P=0.02). Intensive therapy was associated with a lower risk of death from cardiovascular causes (hazard ratio, 0.43; 95% CI, 0.19 to 0.94; P=0.04) and of cardiovascular events (hazard ratio, 0.41; 95% CI, 0.25 to 0.67; P<0.001). One patient in the intensive-therapy group had progression to end-stage renal disease, as compared with six patients in the conventional-therapy group (P=0.04). Fewer patients in the intensive-therapy group required retinal photocoagulation (relative risk, 0.45; 95% CI, 0.23 to 0.86; P=0.02). Few major side effects were reported.

Conclusions In at-risk patients with type 2 diabetes, intensive intervention with multiple drug combinations and behavior modification had sustained beneficial effects with respect to vascular complications and on rates of death from any cause and from cardiovascular causes. (ClinicalTrials.gov number, NCT00320008 [ClinicalTrials.gov] .)

Source Information

From the Steno Diabetes Center, Copenhagen (P.G., H.L.-A., O.P.); Department of Ophthalmology, Glostrup University Hospital, Glostrup (H.L.-A.); Department of Medical Endocrinology, Rigshospitalet Copenhagen University Hospital, Copenhagen (H.-H.P.); and Faculty of Health Sciences, University of Aarhus, Aarhus (H.-H.P., O.P.) — all in Denmark.

Address reprint requests to Dr. Pedersen at the Steno Diabetes Center, 2820 Gentofte, Copenhagen, Denmark, or at oluf{at}steno.dk.

Full Text of this Article

Related Letters:

Multifactorial Intervention and Mortality in Type 2 Diabetes
Schroeder S. A., Tayek J. A., Gæde P., Parving H.-H., Pedersen O.
Extract | Full Text | PDF  
N Engl J Med 2008; 358:2292-2293, May 22, 2008. Correspondence

This article has been cited by other articles:

• Song, S.H., Hardisty, C.A. (2009). Early onset type 2 diabetes mellitus: a harbinger for complications in later years--clinical observation from a secondary care cohort. QJM 102: 799-806 [Abstract] [Full Text]  
• van der Heijden, A. A.W.A., Ortegon, M. M., Niessen, L. W., Nijpels, G., Dekker, J. M. (2009). Prediction of Coronary Heart Disease Risk in a General, Pre-Diabetic, and Diabetic Population During 10 Years of Follow-up: Accuracy of the Framingham, SCORE, and UKPDS Risk Functions: The Hoorn Study. Diabetes Care 32: 2094-2098 [Abstract] [Full Text]  
• Raz, I. (2009). Introduction to the Second World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy): Dilemmas in clinical practice. Diabetes Care 32: S149-S150 [Full Text]  
• Del Prato, S., Penno, G., Miccoli, R. (2009). Changing the Treatment Paradigm for Type 2 Diabetes. Diabetes Care 32: S217-S222 [Full Text]  
• Nilsson, P. M. (2009). Hypertension and Diabetes: Should We Treat Early Surrogates?: What are the cons?. Diabetes Care 32: S290-S293 [Full Text]  
• Davidson, J. A., Parkin, C. G. (2009). Is Hyperglycemia a Causal Factor in Cardiovascular Disease?: Does proving this relationship really matter? Yes. Diabetes Care 32: S331-S333 [Full Text]  
• Kassem, S. A., Raz, I. (2009). Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity or Mortality? No. Diabetes Care 32: S337-S341 [Full Text]  
• Bianchi, C., Miccoli, R., Daniele, G., Penno, G., Del Prato, S. (2009). Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity/Mortality? Yes. Diabetes Care 32: S342-S348 [Full Text]  
• Stirban, A., Tschoepe, D., Stratmann, B. (2009). Shifting the Disease Management Paradigm From Glucose: What are the pros?. Diabetes Care 32: S349-S352 [Full Text]  
• Heller, S. R., on behalf of the ADVANCE Collaborative Group, (2009). A Summary of the ADVANCE Trial. Diabetes Care 32: S357-S361 [Full Text]  
• Eldor, R., Raz, I. (2009). American Diabetes Association Indications for Statins in Diabetes: Is there evidence?. Diabetes Care 32: S384-S391 [Full Text]  
• Pfeffer, M. A., Burdmann, E. A., Chen, C.-Y., Cooper, M. E., de Zeeuw, D., Eckardt, K.-U., Feyzi, J. M., Ivanovich, P., Kewalramani, R., Levey, A. S., Lewis, E. F., McGill, J. B., McMurray, J. J.V., Parfrey, P., Parving, H.-H., Remuzzi, G., Singh, A. K., Solomon, S. D., Toto, R., the TREAT Investigators, (2009). A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease. NEJM 0: NEJMoa0907845v1-1 [Abstract] [Full Text]  
• Roden, M. (2009). Optimal Insulin Treatment in Type 2 Diabetes. NEJM 361: 1801-1803 [Full Text]  
• Mann, D. M., Woodward, M., Ye, F., Krousel-Wood, M., Muntner, P. (2009). Trends in Medication Use Among US Adults With Diabetes Mellitus: Glycemic Control at the Expense of Controlling Cardiovascular Risk Factors. Arch Intern Med 169: 1718-1720 [Full Text]  
• McWilliams, J. M., Meara, E., Zaslavsky, A. M., Ayanian, J. Z. (2009). Medicare Spending for Previously Uninsured Adults. ANN INTERN MED 0: 0000605-200912010-00149v1-E-149 [Abstract] [Full Text]  
• Bailey, C. J., Blonde, L., Del Prato, S., Leiter, L. A., Nesto, R., Global Partnership for Effective Diabetes Manageme, (2009). What are the practical implications for treating diabetes in light of recent evidence? Updated recommendations from the Global Partnership for Effective Diabetes Management. Diabetes and Vascular Disease Research 6: 283-287 [Abstract]  
• Postma, M. J., de Zeeuw, D. (2009). The economic benefits of preventing end-stage renal disease in patients with type 2 diabetes mellitus. Nephrol Dial Transplant 24: 2975-2983 [Full Text]  
• Li, Q., Li, J., Ren, J. (2009). UCF-101 mitigates streptozotocin-induced cardiomyocyte dysfunction: role of AMPK. Am. J. Physiol. Endocrinol. Metab. 297: E965-E973 [Abstract] [Full Text]  
• Kelly, T. N., Bazzano, L. A., Fonseca, V. A., Thethi, T. K., Reynolds, K., He, J. (2009). Systematic Review: Glucose Control and Cardiovascular Disease in Type 2 Diabetes. ANN INTERN MED 151: 394-403 [Abstract] [Full Text]  
• Li, Q., Hueckstaedt, L. K., Ren, J. (2009). The protease inhibitor UCF-101 ameliorates streptozotocin-induced mouse cardiomyocyte contractile dysfunction in vitro: role of AMP-activated protein kinase. Exp Physiol 94: 984-994 [Abstract] [Full Text]  
• Saydah, S., Tao, M., Imperatore, G., Gregg, E. (2009). GHb Level and Subsequent Mortality Among Adults in the U.S.. Diabetes Care 32: 1440-1446 [Abstract] [Full Text]  
• Laurent, S., Briet, M., Boutouyrie, P. (2009). Large and Small Artery Cross-Talk and Recent Morbidity-Mortality Trials in Hypertension. Hypertension 54: 388-392 [Full Text]  
• Havas, S. (2009). Treatment of Type 2 Diabetes: One Extreme to Another--Reply. Arch Intern Med 169: 1247-1247 [Full Text]  
• Holbrook, A., Thabane, L., Keshavjee, K., Dolovich, L., Bernstein, B., Chan, D., Troyan, S., Foster, G., Gerstein, H., for the COMPETE II Investigators, (2009). Individualized electronic decision support and reminders to improve diabetes care in the community: COMPETE II randomized trial. CMAJ 181: 37-44 [Abstract] [Full Text]  
• Hemmingsen, B., Lund, S. S, Wetterslev, J., Vaag, A. (2009). Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes. Eur J Endocrinol 161: 1-9 [Abstract] [Full Text]  
• O'Connor, P. J., Crain, A. L., Rush, W. A., Hanson, A. M., Fischer, L. R., Kluznik, J. C. (2009). Does Diabetes Double the Risk of Depression?. Ann Fam Med 7: 328-335 [Abstract] [Full Text]  
• van Biesen, W., Van Laecke, S., Vanholder, R. (2009). Treatment of type 2 diabetes in chronic kidney disease: meekly follow the herd or call to arms?. Nephrol Dial Transplant 24: 2286-2287 [Full Text]  
• Morath, C., Zeier, M. (2009). Transplantation in type 1 diabetes. Nephrol Dial Transplant 24: 2026-2029 [Full Text]  
• Amarenco, P., Goldstein, L. B., Messig, M., O'Neill, B. J., Callahan, A. III, Sillesen, H., Hennerici, M. G., Zivin, J. A., Welch, K.M.A., on behalf of the SPARCL Investigators, (2009). Relative and Cumulative Effects of Lipid and Blood Pressure Control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trial. Stroke 40: 2486-2492 [Abstract] [Full Text]  
• The BARI 2D Study Group, (2009). A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease. NEJM 360: 2503-2515 [Abstract] [Full Text]  
• Montori, V. M., Fernandez-Balsells, M. (2009). Glycemic Control in Type 2 Diabetes: Time for an Evidence-Based About-Face?. ANN INTERN MED 150: 803-808 [Abstract] [Full Text]  
• Clement, M., Bhattacharyya, O., Conway, J. R. (2009). Is tight glycemic control in type 2 diabetes really worthwhile?: YES. cfp 55: 580-582 [Full Text]  
• Clement, M., Bhattacharyya, O., Conway, J. R. (2009). Vaut-il vraiment la peine d'exercer un strict controle glycemique pour le diabete de type 2?: OUI. cfp 55: 584-588 [Full Text]  
• Chan, J. C., So, W.-Y., Yeung, C.-Y., Ko, G. T., Lau, I.-T., Tsang, M.-W., Lau, K.-P., Siu, S.-C., Li, J. K., Yeung, V. T., Leung, W. Y., Tong, P. C., for the SURE Study Group, (2009). Effects of Structured Versus Usual Care on Renal Endpoint in Type 2 Diabetes: The SURE Study: A randomized multicenter translational study. Diabetes Care 32: 977-982 [Abstract] [Full Text]  
• Marshall, S. M. (2009). Intensive Diabetes Management for High-Risk Patients: How Best to Deliver?. Diabetes Care 32: 1132-1133 [Full Text]  
• Bartnik, M., Cosentino, F. (2009). Dysglycaemia, cardiovascular outcome and treatment. Is the jury still out?. Eur Heart J 30: 1301-1304 [Full Text]  
• Kavanagh, P L, Adams, W G, Wang, C J (2009). Quality indicators and quality assessment in child health. Arch. Dis. Child. 94: 458-463 [Abstract] [Full Text]  
• Chan, J. C. N., Malik, V., Jia, W., Kadowaki, T., Yajnik, C. S., Yoon, K.-H., Hu, F. B. (2009). Diabetes in Asia: Epidemiology, Risk Factors, and Pathophysiology. JAMA 301: 2129-2140 [Abstract] [Full Text]  
• Song, S. H (2009). Early-onset type 2 diabetes: not a benign condition. British Journal of Diabetes & Vascular Disease 9: 137-138  
• Parving, H.-H., Brenner, B. M., McMurray, John. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Ghadanfar, M., Weissbach, N., Xiang, Z., Armbrecht, J., Pfeffer, M. A. (2009). Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 24: 1663-1671 [Abstract] [Full Text]  
• Cheng, A. Y.Y., Leiter, L. A. (2009). Cardiovascular risk and glycemic control. CMAJ 180: 907-908 [Full Text]  
• Kahn, S. E. (2009). Glucose Control in Type 2 Diabetes: Still Worthwhile and Worth Pursuing. JAMA 301: 1590-1592 [Full Text]  
• Sanz, J., Moreno, P. R., Fuster, V. (2009). The year in atherothrombosis.. J Am Coll Cardiol 53: 1326-1337 [Full Text]  
• Oster, R. T., Virani, S., Strong, D., Shade, S., Toth, E. L. (2009). Diabetes care and health status of First Nations individuals with type 2 diabetes in Alberta. cfp 55: 386-393 [Abstract] [Full Text]  
• O'Connor, P. J., Sperl-Hillen, J. M. (2009). The Role of Diabetes Educators in the Medical Home. Diabetes Spectr. 22: 124-126 [Full Text]  
• Collins, A. R., Lyon, C. J., Xia, X., Liu, J. Z., Tangirala, R. K., Yin, F., Boyadjian, R., Bikineyeva, A., Pratico, D., Harrison, D. G., Hsueh, W. A. (2009). Age-Accelerated Atherosclerosis Correlates With Failure to Upregulate Antioxidant Genes. Circ. Res. 104: e42-e54 [Abstract] [Full Text]  
• Ceriello, A. (2009). Postprandial Hyperglycemia and Cardiovascular Disease: Is the HEART2D study the answer?. Diabetes Care 32: 521-522 [Full Text]  
• Gulliford, M. C., Charlton, J. (2009). Is Relative Mortality of Type 2 Diabetes Mellitus Decreasing?. Am J Epidemiol 169: 455-461 [Abstract] [Full Text]  
• Sun, Q., Yue, P., Deiuliis, J. A., Lumeng, C. N., Kampfrath, T., Mikolaj, M. B., Cai, Y., Ostrowski, M. C., Lu, B., Parthasarathy, S., Brook, R. D., Moffatt-Bruce, S. D., Chen, L. C., Rajagopalan, S. (2009). Ambient Air Pollution Exaggerates Adipose Inflammation and Insulin Resistance in a Mouse Model of Diet-Induced Obesity. Circulation 119: 538-546 [Abstract] [Full Text]  
• Masood, S, Jayne, D, Karim, Y (2009). Beyond immunosuppression - challenges in the clinical management of lupus nephritis. Lupus 18: 106-115 [Abstract]  
• Chan, J. C.N., Gagliardino, J. J., Baik, S. H., Chantelot, J.-M., Ferreira, S. R.G., Hancu, N., Ilkova, H., Ramachandran, A., Aschner, P., on behalf of the IDMPS Investigators, (2009). Multifaceted Determinants for Achieving Glycemic Control: The International Diabetes Management Practice Study (IDMPS). Diabetes Care 32: 227-233 [Abstract] [Full Text]  
• Skyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A.M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., Sherwin, R. S. (2009). Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A Position Statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 53: 298-304 [Full Text]  
• Skyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A.M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., Sherwin, R. S. (2009). Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A Position Statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 119: 351-357 [Full Text]  
• Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., Warren, S. R., Goldman, S., McCarren, M., Vitek, M. E., Henderson, W. G., Huang, G. D., the VADT Investigators, (2009). Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. NEJM 360: 129-139 [Abstract] [Full Text]  
• Bhattacharyya, O. K., Estey, E. A., Cheng, A. Y.Y. (2009). Update on the Canadian Diabetes Association 2008 clinical practice guidelines. cfp 55: 39-43 [Full Text]  
• Skyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A.M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., Sherwin, R. S. (2009). Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association . Diabetes Care 32: 187-192 [Full Text]  
• American Diabetes Association, (2009). Standards of Medical Care in Diabetes--2009. Diabetes Care 32: S13-S61 [Full Text]  
• Cosentino, F., Rydén, L., Francia, P., Mellbin, L. G. (2009). CHAPTER 14 Diabetes Mellitus and Metabolic Syndrome. ESC Textbook of Cardiovascular Medicine 2: med-9780199566990-chapter-med-9780199566990-chapter [Abstract] [Full Text]  
• Montori, V. M, Malaga, G. (2008). Intensive glucose control did not prevent important complications in type 2 diabetes. Evid. Based Med. 13: 168-169 [Full Text]  
• Mugarza, J. A, Wilding, J. P, Woodward, A., Hayden, K., Gill, G. V (2008). Achieving blood pressure control in patients with type 2 diabetes and diabetic renal disease by a nurse-led protocol based clinic. British Journal of Diabetes & Vascular Disease 8: 279-284 [Abstract]  
• Anselmino, M., Wallander, M., Norhammar, A., Mellbin, L., Ryden, L. (2008). Implications of abnormal glucose metabolism in patients with coronary artery disease. Diabetes and Vascular Disease Research 5: 285-290 [Abstract]  
• Fruchart, J.-C., Sacks, F. M, Hermans, M. P, Assmann, G., Brown, W V., Ceska, R., Chapman, M J., Dodson, P. M, Fioretto, P., Ginsberg, H. N, Kadowaki, T., Lablanche, J.-M., Marx, N., Plutzky, J., Reiner, Z., Rosenson, R. S, Staels, B., Stock, J. K, Sy, R., Wanner, C., Zambon, A., Zimmet, P. (2008). The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. Diabetes and Vascular Disease Research 5: 319-335 [Abstract]  
• Schonauer, M., Thomas, A., Morbach, S., Niebauer, J., Schonauer, U., Thiele, H. (2008). Cardiac autonomic diabetic neuropathy. Diabetes and Vascular Disease Research 5: 336-344 [Abstract]  
• So, W.-Y., Wang, Y., Ng, M. C.Y., Yang, X., Ma, R. C.W., Lam, V., Kong, A. P.S., Tong, P. C.Y., Chan, J. C.N. (2008). Aldose Reductase Genotypes and Cardiorenal Complications: An 8-year prospective analysis of 1,074 type 2 diabetic patients. Diabetes Care 31: 2148-2153 [Abstract] [Full Text]  
• Bhattacharyya, O. K. MD PhD, Shah, B. R. MD PhD, Booth, G. L. MD MSc (2008). Management of cardiovascular disease in patients with diabetes: the 2008 Canadian Diabetes Association guidelines. CMAJ 179: 920-926 [Full Text]  
• Home, P. (2008). Tight control of blood glucose and cardiovascular disease. BMJ 337: a2105-a2105 [Full Text]  
• Chalmers, J., Cooper, M. E. (2008). UKPDS and the Legacy Effect. NEJM 359: 1618-1620 [Full Text]  
• Holman, R. R., Paul, S. K., Bethel, M. A., Neil, H. A. W., Matthews, D. R. (2008). Long-Term Follow-up after Tight Control of Blood Pressure in Type 2 Diabetes. NEJM 359: 1565-1576 [Abstract] [Full Text]  
• Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., Neil, H. A. W. (2008). 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. NEJM 359: 1577-1589 [Abstract] [Full Text]  
• HOOGWERF, B. J. (2008). Does intensive therapy of type 2 diabetes help or harm? Seeking accord on ACCORD. Cleveland Clinic Journal of Medicine 75: 729-737 [Abstract] [Full Text]  
• Kidambi, S., Patel, S. B. (2008). Diabetes Mellitus: Considerations for Dentistry. Journal of the American Dental Association 139: 8S-18S [Abstract] [Full Text]  
• Cederholm, J., Eeg-Olofsson, K., Eliasson, B., Zethelius, B., Nilsson, P. M., Gudbjornsdottir, S., on behalf of the Swedish National Diabetes Registe, (2008). Risk Prediction of Cardiovascular Disease in Type 2 Diabetes: A risk equation from the Swedish National Diabetes Register. Diabetes Care 31: 2038-2043 [Abstract] [Full Text]  
• Boekholdt, S. M., de Winter, R. J., Kastelein, J. J.P. (2008). Inhibition of Lipoprotein-Associated Phospholipase Activity by Darapladib: Shifting Gears in Cardiovascular Drug Development: Are Antiinflammatory Drugs the Next Frontier?. Circulation 118: 1120-1122 [Full Text]  
• Bailey, C. J, Day, C. (2008). Glycaemic memory. British Journal of Diabetes & Vascular Disease 8: 242-247 [Abstract]  
• Escobar, C., Barrios, V. (2008). Risk Factors Control in Diabetes: The "Real World" of Clinical Practice. The Diabetes Educator 34: 763-764 [Full Text]  
• Shah, B. R. (2008). Utilization of physician services for diabetic patients from ethnic minorities. J Public Health (Oxf) 30: 327-331 [Abstract] [Full Text]  
• Charlton, J., Latinovic, R., Gulliford, M. C. (2008). Explaining the Decline in Early Mortality in Men and Women With Type 2 Diabetes: A population-based cohort study. Diabetes Care 31: 1761-1766 [Abstract] [Full Text]  
• Triplitt, C., Alvarez, C. A. (2008). Best Practices for Lowering the Risk of Cardiovascular Disease in Diabetes. Diabetes Spectr. 21: 177-189 [Abstract] [Full Text]  
• Gouni-Berthold, I., Berthold, H. K., Mantzoros, C. S., Bohm, M., Krone, W. (2008). Sex Disparities in the Treatment and Control of Cardiovascular Risk Factors in Type 2 Diabetes. Diabetes Care 31: 1389-1391 [Abstract] [Full Text]  
• Dluhy, R. G., McMahon, G. T. (2008). Intensive Glycemic Control in the ACCORD and ADVANCE Trials. NEJM 358: 2630-2633 [Full Text]  
• The ADVANCE Collaborative Group, (2008). Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. NEJM 358: 2560-2572 [Abstract] [Full Text]  
• Karalliedde, J., Gnudi, L. (2008). ACCORD and ADVANCE: a tale of two studies on the merits of glycaemic control in type 2 diabetic patients. Nephrol Dial Transplant 23: 1796-1798 [Full Text]  
• Bloomgarden, Z. T. (2008). Cardiovascular Disease in Diabetes. Diabetes Care 31: 1260-1266 [Full Text]